Ono Pharmaceutical Co. Ltd

Quick facts

Marketed products

• Adlumiz · Oncology
• Sivelestat sodium hydrate

Phase 3 pipeline

• Docetaxel/Paclitaxel · Oncology
  Docetaxel and paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis.
• FOY-305 · Cardiovascular
  FOY-305 is a Factor IIa (thrombin) inhibitor that blocks the coagulation cascade to prevent thrombotic events.
• imidafenacin, KRP-197/ONO-8025 · Urology
  Imidafenacin is an antimuscarinic agent that acts as a selective M3 receptor antagonist.
• Minodronic acid hydrate · Bone metabolism / Osteoporosis
  Minodronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
• MK-0431/ONO-5435 · Diabetes
  MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.
• ONO-1101 · Oncology
  ONO-1101 is a monoclonal antibody targeting PD-1.
• ONO-4059 · Oncology
  ONO-4059 is a small-molecule inhibitor of phosphoinositide 3-kinase (PI3K) that blocks PI3K signaling to suppress tumor cell proliferation and survival.
• ONO-4538 · Oncology
  ONO-4538 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• ONO-5920 · Cardiovascular
  ONO-5920 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.
• ONO-8025 (KRP-197) · Cardiovascular
  ONO-8025 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.
• Placebo, MK-0431/ONO-5435 · Diabetes
  MK-0431/ONO-5435 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.

Phase 2 pipeline

• ONO-1110
• ONO-2020
• ONO-2506PO
• ONO-2808
• ONO-4578
• ONO-5046Na
• ONO-7436
• ONO-8577

Phase 1 pipeline

• [14C]ONO-4053
• [14C]-ONO-5788
• Calcium Levofolinate Hydrateb
• KLH, ONO-4685
• ONO-4474 Part A1
• ONO-4474 Part A2
• ONO-4474 Part B
• ONO-4474 Part C
• ONO-4474 Part D
• ONO-4538HSC
• ONO-4685
• ONO-7018
• ONO-7428
• ONO-7475
• ONO-7913

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ono Pharmaceutical Co. Ltd portfolio CI brief
• Ono Pharmaceutical Co. Ltd pipeline updates RSS